Brief: CogState Ltd Says 1H23 Clinical Trials Revenue Expected To Be Consistent With 2H22

Cogstate

30/08/2022 24:23

Aug 30 (Reuters) - CogState Ltd  CGS.AX :
    * 1H23 CLINICAL TRIALS REVENUE EXPECTED TO BE CONSISTENT
WITH 2H22
    * CLINICAL TRIALS REVENUE FOR 2H23 WILL VARY WITH LEVEL OF
SALES
CONTRACTS AND THEREFORE UNABLE TO BE ACCURATELY FORECAST AT THIS
TIME
    * FY23 HEALTHCARE REVENUE AND SEGMENT CONTRIBUTION EXPECTED
TO BE
CONSISTENT WITH FY22
    * SEES FY23 EBIT, BASED ON CURRENT REVENUE FORECAST,
EXPECTED TO
BE AT BOTTOM END OF TARGET RANGE OF 20% - 24% OF REVENUE
    * SEES FY23 OPERATING CASHFLOW OF ABOUT 75% OF EBITDA
    * FY23 EBITDA TARGETED TO BE IN RANGE OF 27% - 29% OF
REVENUE

Source text for Eikon:  ID:nASX7RPXGP 
Further company coverage:  CGS.AX 

 ((Reuters.Briefs@thomsonreuters.com;))